Skip to main content
Explore URMC

menu

Lung Cancer (NSCLC): Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer Carrying an ALK or ROS1 Rearrangement

Research Question:
There is no research question. This is an expanded access program.

Basic Study Information

Purpose:
This is an expanded access program. The program is sponsored by the pharmaceutical company named Pfizer, Inc. (the "Sponsor"). The purpose of this program is to allow patients with advanced non-small cell lung cancer access to lorlatinib treatment and to find out the good and bad effects of this drug.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03178071?term=B7461020&rank=1
Study Reference #: ELUN17127

Lead Researcher (Principal Investigator)

Lead Researcher: Deborah Mulford, MD

Study Contact Information

Study Coordinator: Amy Jasek
Phone: (585) 273-1912
Email: Amy_Jasek@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Lung Cancer

Return to Search